TY - JOUR T1 - Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer JF - medRxiv DO - 10.1101/2020.04.29.20085738 SP - 2020.04.29.20085738 AU - Christine M. Lovly AU - Kelli L. Boyd AU - Paula I. Gonzalez-Ericsson AU - Cindy L. Lowe AU - Hunter M. Brown AU - Robert D. Hoffman AU - Brent C. Sterling AU - Meghan E. Kapp AU - Douglas B. Johnson AU - Prasad R. Kopparapu AU - Wade T. Iams AU - Melissa A. Warren AU - Michael J. Noto AU - Brian I. Rini AU - Madan Jagasia AU - Suman R. Das AU - Justin M. Balko Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/01/2020.04.29.20085738.abstract N2 - Immune checkpoint inhibitors (ICIs) are used for the treatment of numerous cancers, but risks associated with ICI-therapy during the COVID-19 pandemic are poorly understood. We report a case of acute lung injury in a lung cancer patient initially treated for ICI-pneumonitis and later found to have concurrent SARS-CoV-2 infection. Post-mortem analyses revealed diffuse alveolar damage in both the acute and organizing phases, with a predominantly CD68+ inflammatory infiltrate. Serum was positive for anti-SARS-CoV-2 IgG, suggesting that viral infection predated administration of ICI-therapy and may have contributed to a more fulminant clinical presentation. These data suggest the need for routine SARS-CoV-2 testing in cancer patients, where clinical and radiographic evaluations may be non-specific.Competing Interest StatementC.M.L. is a consultant/advisory board member for Foundation Medicine, Pfizer, Novartis, AstraZeneca, Genoptix, Sequenom, Ariad, Takeda, Blueprints Medicine, Cepheid, Achilles, Genentech, Eli Lilly, and reports receiving commercial research grants from Xcovery and Novartis. D.B.J. is a consultant/advisory board member for Array Biopharma, BMS, Jansen, Merck, and Novartis, and receives research funding from BMS and Incyte. W.T.I. reports consulting for Genentech, Outcomes Insights, and Defined Health. J.M.B. receives research support from Genentech/Roche, Bristol Myers Squibb, and Incyte Corporation, and has received consulting/expert witness fees from Novartis. B.I.R. receives research funding from Merck, Roche, Pfizer, AVEO, Peloton, BMS, Astra-Zeneca, owns stock in PTC Therapeutics, and has done consulting for Merck, Roche, Pfizer, AVEO, Peloton, BMS, Arravive, 3D Medicines, Synthorx. M.J. is a consultant for Incyte, Kadmon, and Mallinckrodt. M.J.N received research funding from Gilead Sciences. No potential conflicts of interest were disclosed by the other authors.Funding StatementC.M.L. was supported by Lung Cancer Foundation of America / International Association for the Study of Lung Cancer Lori Monroe Scholarship, NCI R01CA227833, P30-CA086485, UG1CA233259, U54CA217450-01, U01CA224276-01, and P01CA129243-12. K.L.B. was supported by S10OD016355 and P30-CA086485. J.M.B and D.B.J were supported by NIH/NCI 1R01CA227481. W.T.I. was supported by NCI Vanderbilt Clinical Oncology Research Career Development Award (VCORCDP) 2K12CA090625-17.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesReviewed the CARE Checklist of information to include when writing a case report. For item #12 in the checklist “The patient should share their perspective in one to two paragraphs on the treatment(s) they received” -- our case report is about a deceased patient, so we were unable to obtain the patient’s perspective on the treatment received. ER -